Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field

Abstract Polygenic factors are estimated to account for an additional 18% of the familial relative risk of breast cancer, with those at the highest level of polygenic risk distribution having a least a twofold increased risk of the disease. Polygenic testing promises to revolutionize health services...

Full description

Bibliographic Details
Main Authors: Tatiane Yanes, Mary-Anne Young, Bettina Meiser, Paul A. James
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Breast Cancer Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13058-020-01260-3
id doaj-dbede4d66a7d496296a6bb6f016017c7
record_format Article
spelling doaj-dbede4d66a7d496296a6bb6f016017c72021-04-02T12:01:06ZengBMCBreast Cancer Research1465-542X2020-02-0122111010.1186/s13058-020-01260-3Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging fieldTatiane Yanes0Mary-Anne Young1Bettina Meiser2Paul A. James3Psychosocial Research Group, Prince of Wales Clinical School, Faculty of Medicine, UNSW SydneyKinghorn Centre for Clinical Genomics, Garvan Institute of Medical ResearchPsychosocial Research Group, Prince of Wales Clinical School, Faculty of Medicine, UNSW SydneyParkville Integrated Familial Cancer Centre, Peter MacCallum Cancer CentreAbstract Polygenic factors are estimated to account for an additional 18% of the familial relative risk of breast cancer, with those at the highest level of polygenic risk distribution having a least a twofold increased risk of the disease. Polygenic testing promises to revolutionize health services by providing personalized risk assessments to women at high-risk of breast cancer and within population breast screening programs. However, implementation of polygenic testing needs to be considered in light of its current limitations, such as limited risk prediction for women of non-European ancestry. This article aims to provide a comprehensive review of the evidence for polygenic breast cancer risk, including the discovery of variants associated with breast cancer at the genome-wide level of significance and the use of polygenic risk scores to estimate breast cancer risk. We also review the different applications of this technology including testing of women from high-risk breast cancer families with uninformative genetic testing results, as a moderator of monogenic risk, and for population screening programs. Finally, a potential framework for introducing testing for polygenic risk in familial cancer clinics and the potential challenges with implementing this technology in clinical practice are discussed.http://link.springer.com/article/10.1186/s13058-020-01260-3Breast cancerPolygenic risk scoreRisk prediction
collection DOAJ
language English
format Article
sources DOAJ
author Tatiane Yanes
Mary-Anne Young
Bettina Meiser
Paul A. James
spellingShingle Tatiane Yanes
Mary-Anne Young
Bettina Meiser
Paul A. James
Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
Breast Cancer Research
Breast cancer
Polygenic risk score
Risk prediction
author_facet Tatiane Yanes
Mary-Anne Young
Bettina Meiser
Paul A. James
author_sort Tatiane Yanes
title Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
title_short Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
title_full Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
title_fullStr Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
title_full_unstemmed Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
title_sort clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
publisher BMC
series Breast Cancer Research
issn 1465-542X
publishDate 2020-02-01
description Abstract Polygenic factors are estimated to account for an additional 18% of the familial relative risk of breast cancer, with those at the highest level of polygenic risk distribution having a least a twofold increased risk of the disease. Polygenic testing promises to revolutionize health services by providing personalized risk assessments to women at high-risk of breast cancer and within population breast screening programs. However, implementation of polygenic testing needs to be considered in light of its current limitations, such as limited risk prediction for women of non-European ancestry. This article aims to provide a comprehensive review of the evidence for polygenic breast cancer risk, including the discovery of variants associated with breast cancer at the genome-wide level of significance and the use of polygenic risk scores to estimate breast cancer risk. We also review the different applications of this technology including testing of women from high-risk breast cancer families with uninformative genetic testing results, as a moderator of monogenic risk, and for population screening programs. Finally, a potential framework for introducing testing for polygenic risk in familial cancer clinics and the potential challenges with implementing this technology in clinical practice are discussed.
topic Breast cancer
Polygenic risk score
Risk prediction
url http://link.springer.com/article/10.1186/s13058-020-01260-3
work_keys_str_mv AT tatianeyanes clinicalapplicationsofpolygenicbreastcancerriskacriticalreviewandperspectivesofanemergingfield
AT maryanneyoung clinicalapplicationsofpolygenicbreastcancerriskacriticalreviewandperspectivesofanemergingfield
AT bettinameiser clinicalapplicationsofpolygenicbreastcancerriskacriticalreviewandperspectivesofanemergingfield
AT paulajames clinicalapplicationsofpolygenicbreastcancerriskacriticalreviewandperspectivesofanemergingfield
_version_ 1721570436215472128